300753.SZ
Jiangsu Apon Medical Technology Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 21.15
−4.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 345.5M | 342.0M | 403.8M | 422.2M | 323.8M |
| Cost of Revenue | 106.4M | 107.9M | 127.5M | 145.4M | 163.8M |
| Gross Profit | 239.1M | 234.1M | 276.3M | 276.7M | 160.0M |
| Operating Expenses | |||||
| R&D Expense | 41.5M | 40.6M | 33.3M | 36.5M | 34.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 72.6M | 74.8M | 77.6M | 80.9M | 64.6M |
| Selling & Marketing Expense | 143.9M | 153.1M | 154.0M | 147.7M | 142.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 264.7M | 275.3M | 271.0M | 270.2M | 246.3M |
| Cost and Expenses | 371.0M | 383.3M | 398.5M | 415.6M | 410.0M |
| Operating Income (EBIT) | (13.4M) | (27.0M) | 23.5M | 14.0M | (88.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (13.1M) | (26.1M) | 21.2M | 13.8M | (90.7M) |
| Income Tax Expense | 431.3K | 747.4K | 10.3M | 5.4M | (14.6M) |
| Bottom Line | |||||
| Net Income | (10.8M) | (24.0M) | 10.8M | 8.3M | (76.0M) |
| Earnings from Cont. Ops | (13.5M) | (26.8M) | 10.9M | 8.5M | (76.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.8M) | (24.0M) | 10.8M | 8.3M | (76.0M) |
| Per Share | |||||
| Basic EPS | (CN¥0.09) | (CN¥0.19) | CN¥0.09 | CN¥0.07 | (CN¥0.60) |
| Diluted EPS | (CN¥0.09) | (CN¥0.19) | CN¥0.09 | CN¥0.07 | (CN¥0.60) |
| Revenue Per Share | CN¥2.74 | CN¥2.71 | CN¥3.20 | CN¥3.35 | CN¥2.57 |
| Shares | |||||
| Basic Shares Outstanding | 126.2M | 126.0M | 126.0M | 126.0M | 126.0M |
| Diluted Shares Outstanding | 126.2M | 126.0M | 126.0M | 126.0M | 126.0M |
| Profitability Metrics | |||||
| EBITDA | — | (7.2M) | 43.4M | 31.6M | (71.2M) |
| D&A | — | 19.8M | 19.9M | 17.7M | 17.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026